Results 61 to 70 of about 2,519 (184)

Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations [PDF]

Journal of Stroke, 2018
Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.
Kazunori Toyoda, Hiroshi Yamagami, Masatoshi Koga   +2 more
doaj   +1 more source

A Retrospective Descriptive Analysis of Consultations Provided by the National Poisons Centre Relating to Medicines on the Aotearoa New Zealand Antidote Stocking Guideline, 2020–2025

Emergency Medicine Australasia, Volume 38, Issue 5, October 2026.
ABSTRACT Objective Many antidotes are relatively rare‐use, indication‐specific medicines with a variable evidence base. In Aotearoa New Zealand, there are no national statistics available on their use. This study aimed to characterize the numbers of cases and advice provided by the Aotearoa New Zealand National Poisons Centre (NZNPC) on the use of true
Eeva‐Katri Kumpula, William Boroughf
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal [PDF]

, 2018
Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians.
Boriani, Giuseppe, Proietti, Marco
core   +1 more source

Consensus Recommendations for Clinical Pharmacist Integration into the Acute Stroke Care Team: Endorsed by the American College of Clinical Pharmacy, Neurocritical Care Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine, and affirmed by the American Academy of Neurology

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 7, July 2026.
Graphical abstract of consensus recommendations for clinical pharmacist integration into the acute stroke care team. ABSTRACT Clinical pharmacists are increasingly recognized as vital contributors to acute stroke care, yet their role remains inconsistently defined and underutilized across health care systems.
Brian W. Gilbert, Caitlin S. Brown, Nicole M. Acquisto, Kellyn K. Engstrom, Kevin J. Mercer, Gavin T. Howington, David E. Zimmerman, Michael Gottlieb, Alicia E. Mattson, Megan A. Rech, Erin D. Wieruszewski, Andrew J. Webb, Brett Faine, Lance C. Ray, Kent A. Owusu, Barbara Voetsch, Dana Gerberi, Kristin Cole, Fernanda Bellolio   +18 more
wiley   +1 more source

Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.

, 2017
Idarucizumab is a specific antagonist for dabigatran etexilate (DE). The recent market authorization of idarucizumab in Europe and the USA may reassure prescribers of DE, as it can increase the safety of the emergency management of patients taking this ...
Ovidiu Vornicu, Sarah Lessire, Douxfils, Jonathan, François Mullier, Dogné, Jean-Michel, Jonathan Douxfils, Dincq, Anne-Sophie, Anne-Sophie Larock, Vornicu, Ovidiu Ionut, Jean-Michel Dogné, Mullier, François, Larock, Anne-Sophie, Lessire, Sarah, Anne-Sophie Dincq   +13 more
core   +1 more source

Idarucizumab, a humanized, monoclonal antibody fragment for immediate reversal of dabigatran

, 2017
Objective: To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, pharmacokinetic properties, efficacy, and safety of this
Kuyumjian, Yara, Miyares, Marta A., Eaves, Shannon   +2 more
core   +1 more source

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Oral anticoagulation (OAC) reduces stroke risk by at least two thirds and mortality by one fourth. The threshold for net clinical benefit of OAC is met when stroke risk exceeds 1%–2% per year. Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists (VKAs) in most patients, including in the elderly and chronic kidney disease ...
Nicolas Johner, Baris Gencer
wiley   +1 more source

Successful use of idarucizumab for the management of intracranial hemorrhage in an elderly woman receiving dabigatran for stroke prevention in atrial fibrillation: A case report

IHJ Cardiovascular Case Reports, 2018
Non-vitamin K antagonist oral anticoagulants are effective for prevention of stroke in atrial fibrillation (AF) but management of emergency situations in some patients receiving these drugs can be challenging.
Manoj Mashru, Mehul S. Shah, Arun B. Shah, Sonesh kalra, Sandeep Bhapkar   +4 more
doaj   +1 more source

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice. [PDF]

, 2016
Background. Immediate reversal of anticoagulation is essential when facing severe bleeding or emergency surgery. Although idarucizumab is approved for the reversal of dabigatran in many countries, clinical experiences are lacking, particularly in special
Sauter, Thomas, Schlittler, Fabian, Blum, Sina, Ricklin, Meret, Nagler, Michael, Exadaktylos, Aristomenis, Exadaktylos AK, Sauter TC, Ricklin ME, Schlittler FL, Blum S, Nagler M   +11 more
core   +2 more sources